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Background: Inﬂammation and oxidative stress have been linked to the origin and persistence of atrial ﬁbrillation
(AF). CHADS-2 scoring system is a risk stratiﬁcation schema well validated in prognostication of stroke in AF.
We evaluated the association of markers of oxidative stress and inﬂammation with CHADS-2 scores in chronic
AF patients.
Methods: CHADS-2 scores were calculated for 64 subjects with chronic AF. Serum markers of inﬂammation
[C-reactive protein (hs-CRP), interleukin-6 (IL-6), interleukin 1β (IL-1β), tumor necrosis factor-α (TNF-α)]
and of oxidative stress [derivatives of reactive oxygen metabolites (DROMs) and isoprostanes (IsoPs)] were
measured.
Results: Twenty subjects were categorized as 0 (no risk), 24 as 1 (intermediate risk) and 20 as 2 (severe risk)
based on their CHADS-2 scores. High sensitivity-CRP (CHADS-2 0 = 40.0%, 1 = 70.0%, 2 = 90.0%; p= 0.003)
and DROMs (CHADS-2 0 = 45%, 1 = 78%, 2 = 80%; p = 0.04) were positively associated with the CHADS-2
risk score. Subjects with intermediate to severe CHADS-2 risk retained signiﬁcant associations with
abnormal hs-CRP (OR: 5.3, 95%CI: 1.1–25.0) and DROMs (adjusted OR: 6.7, 95%CI: 1.2–38.8) after adjusting
for gender and hypertension. In a multiple logistic interaction model, there was no signiﬁcant interaction
between hs-CRP and DROMs in their association with CHADS-2 risk categories (p = 0.64). A biomarker
risk-model, combining hs-CRP and DROMs, correlated well with the CHADS-2 risk categories (r = 0.49,
p b 0.001).
Conclusions: A biomarker risk-model using a combination of hs-CRP and DROMs correlates well with
CHADS-2 risk scores in chronic AF. Either or both of these markers may add predictive power to future
stroke risk prediction models.
© 2015 The Authors. Published by Elsevier Ireland Ltd. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Stroke is the most debilitating complication of chronic atrial ﬁbrilla-
tion (AF) [1,2]. Major risk factors for stroke include a history of a prior
stroke or transient ischemic attack (TIA), presence of hypertensiontional Institutes of Health (NIH)
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nd Ltd. This is an open access article unor diabetes, age N 75 years, and poor left ventricular function [2]. Long
term anticoagulation helps prevention of this drastic complication of
chronic AF [3]. The chronic use of anticoagulation involves consider-
ation of associated risks of life threatening bleeding [4]. Several risk
stratiﬁcation scoring schemes [5,6] have been developed to determine
which patients with chronic AF have the highest stroke risk and, thus,
would beneﬁt the most with chronic anticoagulation. Most widely
used among these is the CHADS-2 risk score [5], where C stands for
congestive heart failure, H for hypertension, A for age greater than or
equal to 75 years, D for diabetes and S for prior strokes or TIAs. Each
of the factors assigns 1 point except for history of TIA or stroke that
adds 2 points. Adjusted stroke rate per 100 patient-years increases as
the CHADS-2 scores increase [5]. Recently, the CHADS-2 score has
been supplementedwith amodiﬁed CHADS-2 Vasc score which also in-
cludes the presence of vascular disease and adds an extra point for age
N75 years [7]. These risk stratiﬁcation schemas help in determiningder the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Fig. 1. Abnormal plasma levels of biomarkers of oxidative stress and inﬂammation across
risk categories by CHADS-2 scores (hs-CRP, high sensitivity C-reactive protein; DROM, de-
rivatives of reactive oxygen metabolites; IL-1β, interleukin Iβ; IL-6, interleukin 6; TNF-α,
tumor necrosis factor-α; Iso-P, isoprostanes).
Table 1









Age (years) 60.0 ± 7.4 57.6 ± 12.4 59.9 ± 17.0 0.8
Males (%) 90.0% 91.7% 65.0% 0.04
Whites (%) 95.0% 87.5% 70% 0.09
BMI (kg/m2) 32.0 ± 9.1 34.4 ± 12.2 34.6 ± 14.8 0.8
Smokers (%) 30.0% 20.8% 10.0% 0.3
HTN (%) 5.3% 75.0% 65.0% b0.001
Diabetes (%) 5.0% 4.3% 20.0% 0.1
Coumadin (%) 90.0% 91.7% 85.0% 0.8
A CHADS-2 score was calculated for each subject by assigning one point each for age N75
years, hypertension, diabetes and heart failure or low ejection fraction, and two points for
history of prior stroke or TIA.
25S.I. Negi et al. / IJC Metabolic & Endocrine 6 (2015) 24–26the need for anticoagulation therapy in patients with chronic AF and
guide physicians in management. Nevertheless, there remains a need
for a reﬁnement in risk prediction models, especially in patients who
fall in the low to intermediate or intermediate risk category on these
risk scores.
Inﬂammation has been linked to the chronicity of AF and its
thrombo-embolic complications [8]. C-reactive protein (CRP), a marker
of inﬂammation, has been associated persistence and recurrence of AF
aswell aswith the incidence of stroke [9]. Recently, markers of systemic
oxidative stress have been associated with AF [10]. Higher levels of the
derivatives of reactive oxygen species (DROMs) and F2-isoprostanes
(IsoPs) are found in patients with persistent AF compared to age-
matched controls [10]. In an animal model, there is evidence of loss of
the antiplatelet agent, nitric oxide, and of endocardial dysfunction in
the left atriumand left atrial appendage duringAF [11,12]. Nevertheless,
it is unknown if elevated levels of thesemarkers are also associatedwith
stroke risk in AF. We aimed to determine if the levels of markers of ox-
idative stress and inﬂammation correlated with CHADS-2 risk score in
patients with chronic atrial ﬁbrillation.
2. Methods
Consecutive subjects with electrocardiographically (ECG) docu-
mented chronic AF were enrolled from clinics at the Atlanta Veterans
Affairs Medical Center and Emory University Afﬁliated hospitals during
years 2004–2006 (NCT00252967). The study protocol conformed to the
ethical guidelines of the 1975 Declaration of Helsinki as reﬂected in a
priori approval by the institution's human research committee. All sub-
jects providedwritten informed consent. AF was deﬁned as the absence
of P waves and irregular RR intervals on ECG. Chronic AFwas deﬁned as
persistent AF for more than a year. Exclusion criteria included age
b18 years, paroxysmal AF, hemodynamic instability, thyroid disor-
ders, uncontrolled hypertension (blood pressure N 180/100 at rest),
presence of inﬂammatory condition or malignancies. Medical re-
cords were reviewed for baseline demographic and clinical data
including presence of cardiovascular disease, hypertension, and dia-
betes, history of strokes or TIAs, left ventricular systolic function and
concomitant medications.
A CHADS-2 score was calculated for each subject by assigning one
point each for age N75 years, hypertension, diabetes and heart failure
or low ejection fraction, and two points for history of prior stroke or
TIA. Hypertension was deﬁned either by historical documentation,
readings obtained of systolic blood pressure ≥140 mm Hg and/or
diastolic blood pressure ≥90 mm Hg, or use of antihypertensive medi-
cation. Diabetes was present if reported by a physician or the patient
was using anti-diabetic agents and/or insulin. The presence of heart fail-
ure was determined either from the medical records or by an ejection
fraction of less than 50% on a recent echocardiogram. History of stroke
or TIA was determined from the medical records.Plasma levels of markers of inﬂammation and oxidative stress were
measured in a non-fasting state. Abnormal levelswere deﬁned using the
upper limit of normal reference range as a cut off. (TNF-α b 8 pg/mL;
IL-6 b 5 pg/mL; IL-1 b 3 pg/mL; hs-CRP b 3mg/L; DROM 250–300 Carr
Units; Isoprostanes 351–685 pg/mL). Markers of oxidative stress
included IsoPs and DROMs. Concentration of DROMs was deter-
mined using spectrometry (505 nm) [13]. IsoPs were quantiﬁed by
gas chromatography/mass spectrometry [14]. Systemic inﬂammato-
ry markers [hs-CRP, interleukin-6 (IL-6), interleukin 1β (IL-1β), and
tumor necrosis factor-α (TNF-α)] were measured using commercially
available assays.
Categorical variables were compared using Chi-square tests while
continuous variables were compared using analyses of variance.
Multiple logistic regression models were used to analyze independent
associations of DROMs and hs-CRP with CHADS-2 risk categories. An
interaction model was used to evaluate covariance between hs-CRP
and DROMs in their association with CHADS-2 risk categories. A bio-
marker riskmodelwas constructed giving a score of 1 for each abnormal
DROMs or hs-CRP value, and this was correlated with CHADS-2 risk
scores.
3. Results
Sixty-four subjects were enrolled. Based on their CHADS-2 scores,
20 subjects were categorized as 0 (no-risk), 24 as 1 (intermediate-risk)
and 20 as 2 (severe-risk). Subjects in the three risk categories were
similar inmean age (p=0.83), smoking status (p=0.29) and diabetes
(p=0.14), but differed in gender distribution (p=0.04) and hyperten-
sion (p b 0.001) (Table 1). CHADS-2 risk categories signiﬁcantly
differed in having abnormal hs-CRP (0 = 40.0%, 1 = 70.0%, 2 = 90.0%;
p = 0.003) and DROMs (0 = 45%, 1 = 78.3%, 2 = 80%; p = 0.04). No
difference was found in IL-1β, IL-6, TNF-α and IsoPs (Fig. 1). Subjects
with intermediate to severe CHADS-2 risk retained signiﬁcant association
with abnormal hs-CRP (OR: 5.3, 95%CI: 1.1–25.0) and DROMs (adjusted
OR: 6.7, 95%CI: 1.2–38.8) after adjusting for gender and hypertension.
There was no signiﬁcant interaction between hs-CRP and DROMs in
their association with CHADS-2 risk categories in multiple logistic
interactionmodel (p=0.64) (Fig. 2). A biomarker riskmodel, combining
hs-CRP and DROMs, correlated well with the CHAD-2 risk categories
(r= 0.49, p b 0.001).
4. Discussion
In our study, plasma levels of hs-CRP, a marker of inﬂammation, and
DROM, a marker of oxidative stress, correlated well with the CHADS-2
risk score in patients with chronic AF. In addition, the combination
of the two biomarkers, i.e. hs-CRP and DROM, correlated better
with CHADS-2 score than either one alone. Though the correlation of
CHADS-2 score with plasma hs-CRP has previously been shown [15],
Fig. 2. Univariate and multivariate adjusted odds ratios of elevated hs-CRP and DROMs
in the intermediate and high risk CHADS-2 risk score categories (hs-CRP, high sensitivity
C-reactive protein; DROMs, derivatives of reactive oxygen metabolites).
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DROMs and the combination of the two biomarkers. The ﬁndings
serve as indirect evidence in support of the causal association of inﬂam-
mation and oxidative stress in the chronicity and thrombogenecity seen
with AF.
C-reactive protein has been associated with chronicity in AF [16].
Studies have shown that levels of CRP correlate with inﬂammation,
ﬁbrosis, and remodeling [17]. In addition, CRP has also been associated
with all-cause mortality and stroke in AF [18–20]. Possibly explaining
the association, the inﬂammatory milieu is pro-coagulant and contrib-
utes to the thromboembolic complications in chronic AF [21].
Oxidative stress plays an important role in the pathogenesis and
chronicity of AF [14,22,23]. Several redox signaling pathways have
been described in AF that increase oxidative stress such as increased
NADPHoxidase activity, nitric oxide synthase uncoupling and upregula-
tion of xanthine oxidase [24–26]. Increased reactive oxygen species
cause electrical, chemical and structural changes in AF, leading to
chronicity and remodeling. In addition, there is activation of NF-κB
and peroxisome proliferator-activated receptor and upregulation of
plasminogen activator inhibitor-1, an important pro-thrombotic mole-
cule, in response to oxidative stress [27]. This explains that the associa-
tion of markers of oxidative stress does correlate with athero-embolic
risk in chronic AF.
4.1. Study limitations
Our study has limitations. Firstly, the small sample size may have
masked the correlation of other markers of inﬂammation and oxidative
stresswith CHADS-2 score. Nevertheless, wewere able to show a statis-
tically signiﬁcant correlation of both hs-CRP and DROMs, and these
markers with high discriminatory value are likely to be useful to
improve stroke risk prediction models. Secondly, our study was cross-
sectional and did not measure stroke risk prospectively. Future studies
will need to determine any added value of these biomarkers to the
current risk prediction scheme in a prospective manner with stroke as
a primary outcome. Moreover, since we only looked at chronic AF
patients, these markers may not be predictive in paroxysmal AF.
In conclusion, both hs-CRP andDROM levels were independently as-
sociated with CHAD-2 risk score. A biomarker risk-prediction model
combining hs-CRP and DROM correlates well with CHAD-2 risk score
and may be clinically useful for risk prediction in the setting of chronic
AF. A combination of the biomarkers of inﬂammation and oxidative
stress in the form of a risk-prediction model may help reﬁne assess-
ments of the thrombo-embolic risk with intermediate CHADS-2 risk
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